View ValuationStarpharma Holdings 将来の成長Future 基準チェック /66Starpharma Holdings利益と収益がそれぞれ年間91.8%と39.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に756% 91.3%なると予測されています。主要情報91.8%収益成長率91.27%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率39.5%将来の株主資本利益率756.05%アナリストカバレッジLow最終更新日02 Apr 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.お知らせ • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.お知らせ • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.お知らせ • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.お知らせ • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.お知らせ • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.お知らせ • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.1m). Market cap is less than US$100m (US$98.3m market cap).お知らせ • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.お知らせ • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.業績と収益の成長予測OTCPK:SPHR.Y - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202838139916/30/2027240-3-316/30/202616-4-4-4112/31/202515-3-1-1N/A9/30/202510-7-4-4N/A6/30/20256-10-7-7N/A3/31/20255-11-9-9N/A12/31/20244-13-11-11N/A9/30/20247-10-9-9N/A6/30/202410-8-7-7N/A3/31/202410-8-7-7N/A12/31/202311-8-7-7N/A9/30/20238-12-11-11N/A6/30/20234-16-15-14N/A3/31/20235-16-12-11N/A12/31/20225-16-8-7N/A9/30/20225-16-11-10N/A6/30/20225-16-14-13N/A3/31/20225-17-18-17N/A12/31/20214-18-21-21N/A9/30/20214-19-18-18N/A6/30/20213-20-15-15N/A3/31/20213-19-13-13N/A12/31/20203-19-11-11N/A9/30/20205-17-11-11N/A6/30/20207-15-11-11N/A3/31/20207-14-10-10N/A12/31/20198-13-8-8N/A9/30/20195-14N/A-9N/A6/30/20193-14N/A-10N/A3/31/20194-13N/A-8N/A12/31/20184-11N/A-6N/A9/30/20185-11N/A-8N/A6/30/20185-10N/A-10N/A3/31/20185-12N/AN/AN/A12/31/20174-13N/A-18N/A9/30/20174-14N/A-18N/A6/30/20174-15N/A-17N/A12/31/20161-20N/A-20N/A9/30/20163-20N/A-19N/A6/30/20165-21N/A-18N/A3/31/20165-22N/A-17N/A12/31/20155-20N/A-16N/A9/30/20153-20N/A-15N/A6/30/20152-19N/A-14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SPHR.Yは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: SPHR.Y今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: SPHR.Y今後 3 年以内に収益を上げることが予想されます。収益対市場: SPHR.Yの収益 ( 39.5% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: SPHR.Yの収益 ( 39.5% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SPHR.Yの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 756 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 11:00終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Starpharma Holdings Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Matthijs SmithCanaccord GenuityDerek JellinekCGS InternationalWaradana Malitha De SilvaCLSA6 その他のアナリストを表示
お知らせ • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.
お知らせ • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.
お知らせ • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.
お知らせ • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.
お知らせ • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.
お知らせ • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.
お知らせ • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$98.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.1m). Market cap is less than US$100m (US$98.3m market cap).
お知らせ • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.
お知らせ • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.